Efficacy and tolerance of BRAF and MEK inhibitors on metastatic melanoma carrying the orphan pV600_K601 delinsE mutation of the BRAF gene

Int J Dermatol. 2021 Jul;60(7):e283-e284. doi: 10.1111/ijd.15538. Epub 2021 Mar 18.

Authors

Jordane Barbé¹, Margaux Garnier¹, Anne Tallet², Christine Collin², Sophie Leducq¹, Émilie Routier³, Laurent Machet¹, Mahtab Samimi¹

Affiliations

¹ Dermatology Department, University Hospital of Tours, Tours, France.
² Platform of Somatic Tumor Molecular Genetics, University Hospital of Tours, Tours, France.
³ Oncology-Dermatology Department, Institut Gustave Roussy, Villejuif, France.

PMID: 33734441
DOI: 10.1111/ijd.15538

No abstract available

Publication types

Letter

MeSH terms

Humans
Melanoma* / drug therapy
Melanoma* / genetics
Mitogen-Activated Protein Kinase Kinases / genetics
Mutation
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf* / genetics

Substances

Protein Kinase Inhibitors
BRAF protein, human
Proto-Oncogene Proteins B-raf
Mitogen-Activated Protein Kinase Kinases